Status:
COMPLETED
Iloprost Therapy in Patients With Critical Limb Ischemia
Lead Sponsor:
Bayer
Conditions:
Peripheral Arterial Disease
Eligibility:
All Genders
18+ years
Brief Summary
Monitoring efficacy and safety aspects of iv. iloprost therapy of patients with critical limb ischemia by recording clinical parameters.
Eligibility Criteria
Inclusion
- Patients who fulfill the internationally defined criteria of critical limb ischemia;
- Patients who are not eligible for vascular surgery or angioplasty interventions and
- Patients who are treated with iloprost infusion.
- The treating physician has decided iloprost treatment before study enrollment.
Exclusion
- Exclusion criteria are in accordance with the Summary of Product Characteristics of Ilomedin.
Key Trial Info
Start Date :
August 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT01458041
Start Date
August 1 2011
End Date
December 1 2014
Last Update
March 2 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Hungary